Second Affiliated Hospital, Zhejiang University, School of Medicine
With
GeneCast Biotechnology Co., Ltd.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patient is ≥ 18 years-old at the time of consent to participate this trial
Famale stage I-III breast cancer patients
HR-positive（ER≥10%）, HER2-negtive invasive breast cancer, either Ki67≥20% and/or PgR\<20%
No prior anti-cancer treatment
ECOG 0-1
You may not be if
Known to have other aggressive malignant tumor in the past 5 years.
Bilateral breast cancer; Inflammatory breast cancer; Occult breast cancer; Distant metastasis confirmed by pathology.
There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia.
Female patients during pregnancy or lactation.
The investigator determines that subjects are not appropriate to participate in the study due to other factors.
Clareo Health | Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
